MA30991B1 - Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 - Google Patents

Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Info

Publication number
MA30991B1
MA30991B1 MA31990A MA31990A MA30991B1 MA 30991 B1 MA30991 B1 MA 30991B1 MA 31990 A MA31990 A MA 31990A MA 31990 A MA31990 A MA 31990A MA 30991 B1 MA30991 B1 MA 30991B1
Authority
MA
Morocco
Prior art keywords
agonists
receptors
benzamide derivatives
compounds
benzamide
Prior art date
Application number
MA31990A
Other languages
English (en)
Inventor
Alessandra Gaiba
Mark Patrick Healy
Christopher Norbert Johnson
Susan Roomans
Steven James Stanway
Martin Edward Swarbrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625098A external-priority patent/GB0625098D0/en
Priority claimed from GB0715145A external-priority patent/GB0715145D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30991B1 publication Critical patent/MA30991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

CETTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU SON DÉRIVÉ PHARMACEUTIQUEMENT ACCEPTABLE, OÙ R1, R2, R3, R4, R5, M, N ET X SONT TELS QUE DÉFINIS DANS LE MÉMOIRE. L'INVENTION DÉCRIT ÉGALEMENT UN PROCÉDÉ PERMETTANT DE PRÉPARER DE TELS COMPOSÉS, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT CES COMPOSÉS, AINSI QUE L'UTILISATION PHARMACOLOGIQUE DE CES COMPOSÉS.
MA31990A 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 MA30991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625098A GB0625098D0 (en) 2006-12-15 2006-12-15 Novel compounds
GB0715145A GB0715145D0 (en) 2007-08-03 2007-08-03 Novel compounds

Publications (1)

Publication Number Publication Date
MA30991B1 true MA30991B1 (fr) 2009-12-01

Family

ID=39149241

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31990A MA30991B1 (fr) 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Country Status (21)

Country Link
US (3) US8314147B2 (fr)
EP (1) EP2101751A1 (fr)
JP (1) JP5069752B2 (fr)
KR (1) KR20090089868A (fr)
AR (1) AR064361A1 (fr)
AU (1) AU2007331471C1 (fr)
BR (1) BRPI0720254A2 (fr)
CA (1) CA2672631A1 (fr)
CL (1) CL2007003640A1 (fr)
CR (1) CR10849A (fr)
DO (1) DOP2009000124A (fr)
EA (1) EA015931B1 (fr)
IL (1) IL198931A0 (fr)
MA (1) MA30991B1 (fr)
MX (1) MX2009006474A (fr)
NO (1) NO20092314L (fr)
NZ (1) NZ577109A (fr)
PE (1) PE20081579A1 (fr)
SG (1) SG177203A1 (fr)
TW (1) TW200848014A (fr)
WO (1) WO2008071736A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172447A4 (fr) * 2007-07-03 2011-08-24 Astellas Pharma Inc Composé amide
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
ES2471919T3 (es) * 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
ES2518919T3 (es) * 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
GB0810313D0 (en) * 2008-06-05 2008-07-09 Glaxo Group Ltd Novel compounds
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
CN104292154A (zh) * 2009-09-29 2015-01-21 葛兰素集团有限公司 新化合物
ES2512727T3 (es) * 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN103068382A (zh) * 2010-07-30 2013-04-24 阿勒根公司 用于皮肤修复的化合物和方法
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012039972A1 (fr) 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Composition pharmaceutique
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2013123275A1 (fr) * 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2765128A1 (fr) 2013-02-07 2014-08-13 Almirall, S.A. Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4
CA2920856C (fr) 2013-08-09 2026-03-03 Ardelyx, Inc. Composes modulant le ph pour diminuer l'absorption gastro-intestinale dephosphate
CA2997692A1 (fr) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Formes cristallines de grapiprant
EP3245186A1 (fr) 2015-01-16 2017-11-22 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé de préparation de composés phénoliques à partir de biomasse
EP3184505A1 (fr) 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé de préparation de composés phénoliques à l'aide d'un catalyseur
WO2020209576A1 (fr) * 2019-04-09 2020-10-15 경희대학교 산학협력단 Composition pharmaceutique pour la prévention ou le traitement d'une lésion de la moelle épinière ou d'une sténose spinale
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN111454150B (zh) * 2019-12-25 2023-03-28 南京工业大学 一种(s)-2-芳基丙酸酯类化合物的合成方法
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (fr) 1998-09-14 2002-09-04 Ono Pharmaceutical Co DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
CA2346038A1 (fr) 1998-10-15 2000-04-20 Merck & Co., Inc. Inhibition de la resorption osseuse
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
ATE336247T1 (de) 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0309200A (pt) 2002-04-12 2005-02-22 Pfizer Uso de ligandos receptores ep4 no tratamento de doenças envolvidas com a il-6
AU2003237520B2 (en) 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (fr) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Derives de pyrrolidine-2-one en tant qu'agonistes du recepteur ep4
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (fr) 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag Derives de 2-piperidone agonistes de la prostaglandine
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
CA2536870C (fr) 2003-09-03 2009-10-27 Pfizer Inc. Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
WO2005116010A1 (fr) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof
ATE533766T1 (de) * 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten

Also Published As

Publication number Publication date
NO20092314L (no) 2009-08-31
US20100022650A1 (en) 2010-01-28
US20080167377A1 (en) 2008-07-10
EP2101751A1 (fr) 2009-09-23
CR10849A (es) 2009-08-12
AU2007331471C1 (en) 2013-07-25
MX2009006474A (es) 2009-06-26
NZ577109A (en) 2011-12-22
SG177203A1 (en) 2012-01-30
US20130261185A1 (en) 2013-10-03
AR064361A1 (es) 2009-04-01
BRPI0720254A2 (pt) 2014-01-07
AU2007331471A1 (en) 2008-06-19
DOP2009000124A (es) 2010-03-31
EA015931B1 (ru) 2011-12-30
EA200970585A1 (ru) 2009-10-30
KR20090089868A (ko) 2009-08-24
TW200848014A (en) 2008-12-16
PE20081579A1 (es) 2009-01-01
US8314147B2 (en) 2012-11-20
JP5069752B2 (ja) 2012-11-07
IL198931A0 (en) 2010-02-17
JP2010513242A (ja) 2010-04-30
AU2007331471B2 (en) 2013-01-10
CL2007003640A1 (es) 2008-07-11
CA2672631A1 (fr) 2008-06-19
WO2008071736A1 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
EP4523747A3 (fr) Composé agoniste du récepteur glp-1r et son utilisation
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA38325B1 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
MA32231B1 (fr) Composés organiques
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
WO2005080384A3 (fr) Dérivé du benzimidazole et ses utilisations
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA30284B1 (fr) Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA31699B1 (fr) Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4